Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.
Sign Up to like & getrecommendations! Published in 2017 at "Oncology letters"
DOI: 10.3892/ol.2016.5525
Abstract: Sorafenib is the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC); however, its therapeutic value in patients with HCC following resection remains controversial. The current retrospective study was undertaken to assess the effects… read more here.
Keywords: high risk; patients advanced; following resection; sorafenib therapy ... See more keywords